Selinexor (2) – Nexpovio®
Multiple myeloma (MM) at least 4 prior therapies, combination with dexamethasone
Characteristics
| Start date | 01.10.2022 – Marketing authorisation: 26.03.2021 |
|---|---|
| Resolution | 16.03.2023 |
| INN | Selinexor |
| Brand name | Nexpovio® |
| Pharm. company | Stemline Therapeutics B.V. |
| G-BA Procedure ID | D-864 |
| ATC code | L01XX66 Other antineoplastic agents (L01XX) |
| Therapeutic area | Oncological diseases |
| Reason for procedure | Initial assessment |
| Specialty | Bundling ACT change |
Studies and Results
- Clinical trials
- The STORM trial is a completed, multicentre, single-arm trial in which the intervention consisted of selinexor plus dexamethasone.
- The XPORT-MM-028 trial is an ongoing, multicentre trial in which, amongst other things, different doses of selinexor and dexamethasone are being compared.
Adults with multiple myeloma who have previously received at least four lines of treatment and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory medicinal products and a monoclonal anti-CD38 antibody, and who have experienced disease progression during their most recent treatment
- The additional benefit is not proven.
Courtesy translation only, please refer to the German original.
Associated procedures
| Selinexor (1) | Nexpovio® | Stemline Therapeutics B.V. | Multiple myeloma (MM) at least 1 prior therapy, combination with bortezomib and dexamethasone | 4,700–7,000 | 100% additional benefit not proven | |
| Selinexor (2) | Nexpovio® | Stemline Therapeutics B.V. | Multiple myeloma (MM) at least 4 prior therapies, combination with dexamethasone | 570–1,130 | 100% additional benefit not proven |
<< List of all resolutions